IKT vs STZ · $215.2M cap vs P/E 14, rev $9.14B
Inhibikase Therapeutics Inc (IKT) versus Constellation Brands Inc Class A (STZ) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Constellation Brands Inc Class A (STZ) is a beverages - brewers company listed on US.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
Latest reported STZ revenue for 2026-02-28 was $9.14B. Net income was $1.69B. Revenue was up 322.3% from 2025-02-28 to 2026-02-28. STZ currently screens at market cap $23.73B and trailing P/E 14.4.
IKT currently screens at market cap $215.2M. STZ currently screens at market cap $23.73B and trailing P/E 14.4.
Not investment advice. Open the IKT and STZ stock pages for the full models.
Not investment advice.